Healthcare company-building profile
Lilly Catalyze360 and Lilly Gateway Labs
Eli Lilly and Company
AcceleratorPharma acceleratorCorporateUncertain
Source-based profile
Program at a Glance
- Program type
- Accelerator
- Program category
- Pharma accelerator
- Organization
- Eli Lilly and Company
- Organization type
- Corporate
- Location
- Indianapolis, Indiana
- Company stage served
- Research or idea stage
- Cohort or participation model
- Rolling engagement across Gateway Labs residency, ExploR&D services and venture investment; no fixed cohort
- Investment or funding offered
- Yes
- Published investment terms
- Varies by track; Gateway Labs residency is fee-based, ExploR&D is a services relationship, and Lilly Ventures makes equity investments
- Equity or fee model
- Equity
- Clinical or hospital connection
- Not publicly documented
- Application status
- Uncertain
- Founded
- 2022
Public description
About the program
Catalyze360 is Lilly's umbrella program for supporting emerging biotech companies, combining Lilly Gateway Labs incubator residency, the ExploR&D scientific advisory and services arm, and Lilly Ventures investment. It gives startups access to Lilly R&D capabilities without requiring them to hand over program rights. Lilly has extended the model with TuneLab, which gives biotechs access to AI-enabled discovery models built on Lilly's research investment.
What the program publicly emphasizes
Focus areas and features
Early-stage biotechDrug discovery and developmentLab incubationAI-enabled discoveryBiotechTherapeuticsLife sciences
- Category: Pharma accelerator
- Program structure: Rolling engagement across Gateway Labs residency, ExploR&D services and venture investment; no fixed cohort
- Published terms: Varies by track; Gateway Labs residency is fee-based, ExploR&D is a services relationship, and Lilly Ventures makes equity investments
Sources
External source links open in a new tab.